Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

While primary central nervous lymphoma (PCNSL) is sensitive to methotrexate chemotherapy, more than half of patients will relapse within five years. Autologous stem-cell transplant (ASCT) is increasingly used as consolidative treatment. This systematic review and meta-analysis provides estimates for response and survival after ASCT and suggests improved rates compared to the historical data.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research